These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 989559)

  • 21. Atypical forms of Guillain-Barré syndrome and H1N1-influenza vaccination.
    Shaikh AG; Termsarasab P; Nwankwo C; Rao-Frisch A; Katirji B
    Vaccine; 2012 May; 30(22):3251-4. PubMed ID: 22429755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Administering influenza vaccine to egg-allergic persons.
    Kelso JM
    Expert Rev Vaccines; 2014 Aug; 13(8):1049-57. PubMed ID: 24962036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parental views on vaccine safety and future vaccinations of children who experienced an adverse event following routine or seasonal influenza vaccination in 2010.
    Parrella A; Gold M; Marshall H; Braunack-Mayer A; Watson M; Baghurst P
    Hum Vaccin Immunother; 2012 May; 8(5):662-7. PubMed ID: 22634441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dermal testing of vaccines for children at high risk of allergies.
    Sugai K; Shiga A; Okada K; Iwata T; Ogura H; Maekawa K; Yokota S
    Vaccine; 2007 Apr; 25(17):3454-63. PubMed ID: 17276555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent Guillain-Barre syndrome following vaccination.
    Baxter R; Lewis N; Bakshi N; Vellozzi C; Klein NP;
    Clin Infect Dis; 2012 Mar; 54(6):800-4. PubMed ID: 22267712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
    Langley JM; Aoki F; Ward BJ; McGeer A; Angel JB; Stiver G; Gorfinkel I; Shu D; White L; Lasko B; Dzongowski P; Papp K; Alexander M; Boivin G; Fries L
    Vaccine; 2011 Feb; 29(10):1921-8. PubMed ID: 21219987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrence risk of oculorespiratory syndrome after influenza vaccination: randomized controlled trial of previously affected persons.
    De Serres G; Skowronski DM; Guay M; Rochette L; Jacobsen K; Fuller T; Duval B
    Arch Intern Med; 2004 Nov; 164(20):2266-72. PubMed ID: 15534165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The generation of the relapse in chronic relapsing experimental allergic encephalomyelitis and multiple sclerosis--parallels and differences.
    Suckling AJ; Kirby JA; Wilson NR; Rumsby MG
    Prog Clin Biol Res; 1984; 146():7-12. PubMed ID: 6609376
    [No Abstract]   [Full Text] [Related]  

  • 29. Establishing the safety of influenza vaccine in egg-allergic individuals.
    Greenhawt MJ
    Pediatr Ann; 2013 Jul; 42(7):122-7. PubMed ID: 23805959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reactogenicity to primary and repeated vaccination with influenza split virus vaccine.
    Hennessen W; Mauler R; Gruschkau H; Lehmann HG
    Dev Biol Stand; 1977 Jun 1-3; 39():289-93. PubMed ID: 604110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Events temporarily associated with anti-influenza A (H1N1) vaccination in Mexico.
    Vidal P; Reyna J; Saldaña P; Richardson VL
    Arch Med Res; 2011 Oct; 42(7):627-32. PubMed ID: 22036935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A generalized reaction to thimerosal from an influenza vaccine.
    Lee-Wong M; Resnick D; Chong K
    Ann Allergy Asthma Immunol; 2005 Jan; 94(1):90-4. PubMed ID: 15702823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
    de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B
    Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.
    Zuccotti G; Amendola A; Viganò A; Pariani E; Zappa A; Pogliani L; Giacomet V; Savarino A; Podestà A; Rottoli A; Tanzi E; Zanetti A; Radaelli G
    Vaccine; 2007 Sep; 25(37-38):6692-8. PubMed ID: 17697730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Active vaccinations in multiple sclerosis].
    Flachenecker P; Toyka KV; Hartung HP
    Dtsch Med Wochenschr; 1995 Nov; 120(44):1513-6. PubMed ID: 7588021
    [No Abstract]   [Full Text] [Related]  

  • 38. [Attitudes and side effects related to pandemic influenza A (H1N1) vaccination in healthcare personnel].
    Ormen B; Türker N; Vardar I; Kaptan F; El S; Ural S; Kaya F; Coşkun NA
    Mikrobiyol Bul; 2012 Jan; 46(1):57-64. PubMed ID: 22399172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preliminary results: surveillance for Guillain-Barré syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine - United States, 2009-2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Jun; 59(21):657-61. PubMed ID: 20520590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple sclerosis: activated cells in cerebrospinal fluid in acute exacerbations.
    Noronha A; Richman DP; Arnason BG
    Ann Neurol; 1985 Dec; 18(6):722-5. PubMed ID: 3841270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.